An appeals panel ruled that the FDA improperly expanded access to the abortion pill mifepristone over the past seven years but left in place the drug's original approval, teeing up the issue for review by the Supreme Court.
An appeals panel ruled that the FDA improperly expanded access to the abortion pill mifepristone over the past seven years but left... #press